EPHA2 mediates PDGFA activity and functions together with PDGFRA as prognostic marker and therapeutic target in glioblastoma

Autor: Qu-Jing Gai, Zhen Fu, Jiang He, Min Mao, Xiao-Xue Yao, Yan Qin, Xi Lan, Lin Zhang, Jing-Ya Miao, Yan-Xia Wang, Jiang Zhu, Fei-Cheng Yang, Hui-Min Lu, Ze-Xuan Yan, Fang-Lin Chen, Yu Shi, Yi-Fang Ping, You-Hong Cui, Xia Zhang, Xindong Liu, Xiao-Hong Yao, Sheng-Qing Lv, Xiu-Wu Bian, Yan Wang

Publikováno v: Signal Transduction and Targeted Therapy, Vol 7, Iss 1, Pp 1-12 (2022)

Abstract Platelet-derived growth subunit A (PDGFA) plays critical roles in development of glioblastoma (GBM) with substantial evidence from TCGA database analyses and in vivo mouse models. So far, only platelet-derived growth receptor α (PDGFRA) has

Externí odkaz: https://doaj.org/article/405264fc1e9d490c8dafcef11c97de0f

Inhibitory effects of temozolomide on glioma cells is sensitized by RSL3-induced ferroptosis but negatively correlated with expression of ferritin heavy chain 1 and ferritin light chain

Autor: Fei-Cheng Yang, Chuan Wang, Jiang Zhu, Qu-Jing Gai, Min Mao, Jiang He, Yan Qin, Xiao-Xue Yao, Yan-Xia Wang, Hui-Min Lu, Mian-Fu Cao, Ming-Min He, Xian-Mei Wen, Ping Leng, Xiong-Wei Cai, Xiao-Hong Yao, Xiu-Wu Bian, Yan Wang

Publikováno v: Laboratory investigation; a journal of technical methods and pathology. 102(7)

Invasive growth of glioblastoma makes residual tumor unremovable by surgery and leads to disease relapse. Temozolomide is widely used first-line chemotherapy drug to treat glioma patients, but development of temozolomide resistance is almost inevitab

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe4ed85aefab8e79129ce179f90a3fa7
https://pubmed.ncbi.nlm.nih.gov/35351965

Comprehensive omics analyses profile genesets related with tumor heterogeneity of multifocal glioblastomas and reveal LIF/CCL2 as biomarkers for mesenchymal subtype.

Autor: Sheng-Qing Lv, Zhen Fu, Lin Yang, Qing-Rui Li, Jiang Zhu, Qu-Jing Gai, Min Mao, Jiang He, Yan Qin, Xiao-Xue Yao, Xi Lan, Yan-Xia Wang, Hui-Min Lu, Yan Xiang, Zuo-Xin Zhang, Guo-Hao Huang, Wei Yang, Ping Kang, Zhijian Sun, Yu Shi

Publikováno v: Theranostics; 2022, Vol. 12 Issue 1, p459-473, 15p

Targeting AKT and CK2 represents a novel therapeutic strategy for SMO constitutive activation‐driven medulloblastoma.

Autor: Yao, Yue‐Liang^1,2 (AUTHOR), Wang, Yan‐Xia¹ (AUTHOR), Yang, Fei‐Cheng¹ (AUTHOR), Wang, Chuan¹ (AUTHOR), Mao, Min¹ (AUTHOR), Gai, Qu‐Jing¹ (AUTHOR), He, Jiang¹ (AUTHOR), Qin, Yan¹ (AUTHOR), Yao, Xiao‐Xue¹ (AUTHOR), Lan, Xi¹ (AUTHOR), Zhu, Jiang¹ (AUTHOR), Lu, Hui‐Min¹ (AUTHOR), Zeng, Hui¹ (AUTHOR), Yao, Xiao‐Hong¹ (AUTHOR), Bian, Xiu‐Wu¹ (AUTHOR), Wang, Yan¹ (AUTHOR) wang_yan1977@hotmail.com

Publikováno v: CNS Neuroscience & Therapeutics. Jul2022, Vol. 28 Issue 7, p1033-1044. 12p.

Inhibitory effects of temozolomide on glioma cells is sensitized by RSL3-induced ferroptosis but negatively correlated with expression of ferritin heavy chain 1 and ferritin light chain.

Autor: Yang, Fei-Cheng, Wang, Chuan, Zhu, Jiang, Gai, Qu-Jing, Mao, Min, He, Jiang, Qin, Yan, Yao, Xiao-Xue, Wang, Yan-Xia, Lu, Hui-Min, Cao, Mian-Fu, He, Ming-Min, Wen, Xian-Mei, Leng, Ping, Cai, Xiong-Wei, Yao, Xiao-Hong, Bian, Xiu-Wu, Wang, Yan

Publikováno v: Laboratory Investigation (00236837); Jul2022, Vol. 102 Issue 7, p741-752, 12p